Press release – Editorial responsibility of Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced the submission to the European Medicines Agency (EMA) of a type II variation for vutrisiran, an investigational RNAi therapy in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran is the generic name of AMVUTTRA ® , currently approved in the European Union (EU) for the treatment of hereditary transthyretin amyloidosis (ATTRv) in adult patients with stage 1 or 2 polyneuropathy.
The original text of this announcement, written in the source language, is the official version that is authentic. Translations are offered solely for the reader’s convenience and must refer to the original language text, which is the only legally valid one.
See the original version on businesswire.com:
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
+1-617-682-4340
Josh Brodsky
(Investors)
+1-617-551-8276
Emily Bunting
(Medium, Europe)
+41 79 866 97 03
Press release – Editorial responsibility of Business Wire
